Radboud university medical center and Quirem Medical signed an agreement for joint research. The agreement includes several existing and future projects based on small radioactive spheres (holmium-166 microspheres). Enhanced cooperation should improve the treatment of cancer patients and stimulate research into new applications.
“Radboudumc strives for continuous improvement of patient care,” says Professor Jurgen Fütterer, intervention radiologist at Radboudumc. “Because we are involved in the development of new treatment techniques, we can tailor these techniques as closely as possible to the needs of the patient. The expansion of our cooperation with Quirem Medical fits in perfectly with that aim.”
The research into holmium microspheres in Radboudumc takes place in the Radiology and Nuclear Medicine department. The 'nuclear local interventions' are carried out in close cooperation with Jurgen Fütterer and other researchers at the Department of Nuclear Medicine. Fütterer: “Our special MITeC operating theatres enable us to use MRI imaging to show the location of the radioactive holmium spheres during the treatment. This allows treatment that is precisely tailored to the individual.”
Quirem Medical, located in Deventer, is the result of previous innovations by the Nijsen research group. “We have also developed radioactive polylactic acid microspheres for the treatment of liver tumors, called radio embolization,” says Fütterer. "We are now focusing on further refining this image-guided treatment to get an even higher dose into patients' liver tumors. We are also working on similar treatments for pancreatic and brain tumors where we will also apply radiation directly to the tissues themselves. These are developing techniques that Quirem Medical, together with Radboudumc, will try to introduce to the clinic in the coming years."
Working together on innovative applications
Quirem Medical develops and produces holmium-166 microspheres for the treatment of tumors. CEO Jan Sigger: “The radioactive holmium microspheres ensure that the tumors are irradiated locally. Moreover, thanks to the holmium, we can see exactly where the microspheres are and whether there are enough microspheres surrounding the tumor. Our technology is currently being used to treat liver tumors that are no longer operable. Radboudumc offers state-of-the-art research, pre-clinical and clinical facilities that offer excellent opportunities to support and accelerate the development of new applications. The high-quality hot lab facilities in the Radboud Translational Medicine center can also help in the further development of our pipeline of innovative, new applications.”
About Quirem Medical
Quirem Medical is a growing medical device company that is developing the next generation of microspheres for targeted interventional treatment of liver tumors. Quirem Medical is based in Deventer, the Netherlands.
Related news items
Vulnerable Nijmegen citizens less likely to visit GP physically due to corona23 February 2021
The COVID-19 pandemic in 2020 in Nijmegen and the surrounding area led to a substantial decrease in GP consultations for patients with chronic physical health problems.read more
New Physical, Mental, and Cognitive Problems 1-year Post-ICU18 February 2021
Half of the Intensive Care Unit (ICU) survivors suffer from new physical, mental and/or cognitive problems one year after ICU admission. This is evident from the large-scale MONITOR-IC study led by the Radboudumc.read more
Trained immunity: a tool for reducing susceptibility to and the severity of SARS-CoV-2 infection17 February 2021
In a review in Cell Mihai Netea, Frank van de Veerdonk, Reinout van Crevel and Jorge Dominguez Andres propose that induction of trained immunity by whole-microorganism vaccines may represent an important tool for reducing susceptibility to and severity of SARS-CoV-2.read more
Radboudumc and Quirem Medical sign cooperation agreement17 February 2021
Radboudumc and Quirem Medical signed an agreement for joint research. The agreement includes several existing and future projects based on small radioactive spheres. Enhanced cooperation should improve the treatment of cancer patients and stimulate research into new applications.read more
Dutch Kidney Foundation Innovation Grant for Tom Nijenhuis and Jeroen de Baaij17 February 2021
This innovation grant was awarded for their project “A sweet deal: repurposing SGLT2i for renal hypomagnesemia”.read more